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Edited by Gerrit van MeerAbstract FAS and FACL3 are enzymes of fatty acid metabo-
lism. In our previous studies, we found that FAS and FACL3
genes were vitamin D3-regulated and involved in the antiprolif-
erative eﬀect of 1a,25(OH)2D3 in the human prostate cancer
LNCaP cells. Here, we elucidated the mechanism behind the
downregulation of FAS expression by vitamin D3. Triacsin C, an
inhibitor of FACL3 activity, completely abolished the downreg-
ulation of FAS expression by vitamin D3, whereas an inhibitor of
FAS activity, cerulenin, had no signiﬁcant eﬀect on the upreg-
ulation of FACL3 expression by vitamin D3 in LNCaP cells. In
human prostate cancer PC3 cells, in which FACL3 expression is
not regulated by vitamin D3, no regulation of FAS expression was
seen. This suggests that the downregulation of FAS expression by
vitamin D3 is mediated by vitamin D3 upregulation of FACL3
expression. Myristic acid, one of the substrates preferential for
FACL3, enhanced the repression of FAS expression by vitamin
D3. The action of myristic acid was abrogated by inhibition of
FACL3 activity, suggesting that the enhancement in the down-
regulation of FAS expression by vitamin D3 is due to the
formation of myristoyl-CoA. The data suggest that vitamin D3-
repression of FAS mRNA expression is the consequence of
feedback inhibition of FAS expression by long chain fatty acyl-
CoAs, which are formed by FACL3 during its upregulation by
vitamin D3 in human prostate cancer LNCaP cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fatty acid synthesis is controlled by a long term and a short
term regulation. The long term regulation of fatty acid syn-
thesis occurs through alterations in the rate of synthesis of
acetyl-CoA carboxylase (ACC), the ﬁrst and rate-limiting en-
zyme of the fatty acid synthesis, and that of fatty acid synthase
(FAS), the second and a key enzyme of the fatty acid synthesis* Corresponding author. Fax: +358-3-215-6170.
E-mail address: shengjun.qiao@uta.ﬁ (S. Qiao).
Abbreviations: FAS, fatty acid synthase; FACL3, long-chain fatty-
acid-CoA ligase 3; ACC, acetyl-CoA carboxylase; acyl-CoA, acyl-
coenzyme A; myristoyl-CoA, myristoyl-coenzyme A
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CoAs [4], but the mechanisms are not fully understood. Inhi-
bition of the de novo fatty acid synthesis by free fatty acids
appears to depend on the formation of long chain fatty acyl-
CoAs [5]. Long chain fatty acyl-CoAs have shown to inhibit
ACC [6–9] and FAS [10]. It is proposed that long chain fatty
acyl-CoAs exert their eﬀects on ACC and FAS by means of
feedback inhibition [10,11]. It is further suggested that the
inhibitory eﬀect of long chain fatty acyl-CoA on the fatty acid
synthesis may be due to its regulation of lipogenic enzymes in a
feedback manner through suppression of the gene transcrip-
tion [12].
Long chain fatty acyl-CoAs are catalytically synthesized by
long-chain fatty-acid-CoA ligase in cells. The inhibitory eﬀect
of long chain fatty acyl-CoAs on the fatty acid synthesis
implies that long-chain fatty-acid-CoA ligase may play an
important role in the suppression of fatty acid synthesis. It
was reported that long-chain fatty-acyl-CoA ligase was in-
volved in the inhibition of fatty acid synthesis [13]. Recently,
we found that FACL3, which utilizes preferentially myristic
acid, eicosapentaenoic acid (EPA), and arachidonic acid as
substrates to form long chain fatty acyl-CoAs, was upregu-
lated by vitamin D3 in both expression and activity levels
and contributed to the growth inhibitory eﬀect of vitamin D3
in human prostate cancer LNCaP cells [14]. We also found
that FAS, which is overexpressed and associated with pros-
tate cancer development, was downregulated by vitamin D3
in LNCaP cells [15]. In the current study, we report that the
downregulation of FAS mRNA by vitamin D3 is due to the
feedback inhibition of FAS expression by long chain fatty
acyl-CoAs, which are synthesized by FACL3, and suggest
that long chain fatty acyl-CoA-mediated inhibition of FAS
expression may be one mechanism by which FACL3 con-
tributes to the antiproliferative eﬀect of vitamin D3 in the
human prostate cancer LNCaP cells.2. Materials and methods
2.1. Reagents
1a,25(OH)2D3 was obtained from Leo Pharmaceuticals (Ballerup,
Denmark). Cerulenin, Myristic acid and triacsin C were purchased
from Sigma (Missouri, USA). RPMI-1640 medium was purchased
from Sigma–Aldrich (Saint Louis, Missouri, USA). FBS was from
Gibco BRL (Life Technology, Paisley, Scotland). TRIzoL reagent wasblished by Elsevier B.V. All rights reserved.
Table 1
The list of primers used for QPCR analysis
Gene names Primer sequences
FACL3 Forward primer: 50-ACTCCACTGTGCGACAGCTTT-30
Reverse primer: 50-CACCACACAACAGGAGACGAA-30
FAS Forward primer: 50-AACTCCAAGGACACAGTCACCAT-30
Reverse primer: 50-CAGCTGCTCCACGAACTCAA-30
GAPDH Forward primer: 50-CCACATCGCTCAGACACCAT-30
Reverse primer: 50-ACCAGGCGCCCAATACG-30
452 S. Qiao, P. Tuohimaa / FEBS Letters 577 (2004) 451–454purchased from Invitrogen (Carlshad, USA). High Capacity DNA
Archive kit and SYBR Green PCR Master Mix Kit were purchased
from Applied Biosystems (Forster City, USA).
2.2. Cell culture and treatments
Human prostate cancer LNCaP cells (from ATCC, USA) were
grown in RPMI-1640 medium supplemented with 10% FBS, 3 mM L-
glutamine, 100 lg/ml streptomycin and 100 U/ml penicillin at 37 C in
a humid atmosphere of 5% CO2. After grown to semi-conﬂuence, the
cells were treated with 1a,25(OH)2D3, triacsin C, cerulenin, myristic
acid or the combination as indicated. For the treatment of
1a,25(OH)2D3 or myristic acid, vehicle ethanol which was received by
the cells was used as a control. Vehicle DMSO was used as a control
for triacsin C or cerulenin treatment.
2.3. RNA preparation
After the treatments, total RNA was isolated using TRIzoL reagent
(Invitrogen, USA) according to the instructions of the manufacturer.
Brieﬂy, 2 ml of TRIzoL reagent was added to a 25 cm2 culture bottle
and passed the cell lysate several times through a pipette for homog-
enization. 400 ll of chloroform was added to each homogenized
sample and mixed it vigorously. After incubation of the sample for 3
min at room temperature, it was centrifuged at 12 000 g for 15 min at
4 C, transferred the aqueous phase to a fresh tube and added an equal
volume of isopropyl alcohol for RNA precipitation. After the pre-
cipitation, the sample was centrifuged as indicated above and RNA
pellet was washed with 75% ethanol. Finally, RNA was redissolved in
RNase-free water and the RNA concentration was measured using
GeneQuant II (Pharmacia Biotech, USA).
2.4. cDNA synthesis
cDNA synthesis from RNA was done using High Capacity Archive
Kit (Applied Biosystems, USA) following the instructions of the
manufacturer. In brief, 10 lg of RNA dissolved in 50 ll of RNase-free
H2O was combined with 50 ll of 2· RT Master Mix (10 ll of 10·
Reverse Transcription Buﬀer, 4 ll of 25· dNTPs, 10 ll of 10· random
primers, 5 ll of MultiScribe Reverse Transcriptase (50 U/ll) and 21 ll
nuclease-free H2O) and the reverse transcription was performed at 25
C for 10 min followed by 37 C for 120 min.
2.5. Real-time quantitative PCR
The real-time quantitative PCR (QPCR) was performed with SYBR
Green PCR Master Mix kit (Applied Biosystems, USA) following the
instructions of the manufacturer in ABI PRISM 7000 Detection Sys-
tem (Applied Biosystems, USA). Brieﬂy, 20 ng of cDNA synthesized
by reverse transcription was combined with primers for the target gene
and 2· SYBR Green PCR Master Mix to the ﬁnal volume of 30 ll per
reaction. The PCR was done at 95 C for 10 min followed by 40 cycles
at 95 C for 15 s, 60 C for 1 min. The product of PCR was checked by
dissociation curve to ensure that the product was speciﬁc for the
studied gene. The data were analyzed by ABI Prism 7000 SDS Soft-
ware and normalized to constitutively expressed glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) to verify uniform sample
loading. The ﬁnal result was expressed as N-fold diﬀerence in gene
expression between treated and untreated samples fNðfoldÞ ¼ ½gene
ðtreatedÞ=GAPDHðtreatedÞ=½geneðuntreatedÞ=GAPDHðuntreatedÞg.
The values used for the calculation in the formula were obtained from
the respective standard curve. The standard curve was made by a series
of dilutions of untreated sample. All primers were designed using
compatible software Primer Express for ABI PRISM 7000 Detection
System. The primers used for QPCR are shown in Table 1.Fig. 1. Inhibition of FACL3 activity by triacsin C abolishes vitamin D32.6. Statistics
Data were analyzed using Student’s t test. A diﬀerence of p < 0:05
was considered as signiﬁcant.
repression of FAS mRNA expression in the human prostate cancer
LNCaP cells. LNCaP cells were grown in RPMI-1640 medium sup-
plemented with 10% FBS and treated with 10 nM 1a,25(OH)2D3, 1
lM triacsin C or the combination of them for 24 h. After the treat-
ments, RNA was isolated and the expression of FAS mRNA was
measured using real-time quantitative PCR. The results represent three
independent experiments and normalized to housekeeping gene
GAPDH. Triacsin C abolished completely the downregulation of FAS
mRNA by 1a,25(OH)2D3. No considerable eﬀect of triacsin C alone
on FAS mRNA expression was seen.3. Results
3.1. FACL3 mediates vitamin D3 inhibition of FAS mRNA
expression
FAS synthesizes fatty acids. FACL3 converts long chain
fatty acid to acyl-CoA for further utilization. In our pre-vious study, we demonstrated that FAS mRNA was de-
creased by vitamin D3 in the human prostate cancer
LNCaP cells and might have a contribution to antiprolif-
erative eﬀect of vitamin D3 [15]. We also found that
FACL3 mRNA and activity were increased by vitamin D3
in LNCaP cells [14]. To investigate whether there is an
association between vitamin D3 downregulation of FAS
expression and its upregulation of FACL3 or the regula-
tions are independent on each other, cerulenin, an inhibitor
of FAS activity, and triacsin C, the inhibitor of FACL3
activity, were applied to treat the cells in the presence or
absence of vitamin D3, and mRNA levels were measured
using real-time QPCR. The results showed that triacsin C
completely abolished vitamin D3 decrease of FAS mRNA
(Fig. 1), whereas cerulenin had no signiﬁcant eﬀect on the
increase in FACL3 mRNA by vitamin D3 (Fig. 2) in
LNCaP cells. Triacsin C had no eﬀect on vitamin D3 up-
regulation of FACL3 mRNA. FAS and FACL3 mRNA
expressions were not aﬀected by cerulenin or triacsin C
alone. In addition, we found in the previous study that
FACL3 expression was not regulated by vitamin D3 in
human prostate cancer PC3 cells [14], which are vitamin D3
responsive and the action of vitamin D3 is independent of
androgen. We measured FAS expression in PC3 cells and
found that FAS expression was not regulated by vitamin D3
(data not shown).
Fig. 2. Inhibition of FAS activity by cerulenin has no signiﬁcant eﬀect
of vitamin D3 upregulation of FACL3 mRNA expression in prostate
cancer LNCaP cells. The cells were grown in RPMI-1640 medium
supplemented with 10% FBS and treated with 10 nM 1a,25(OH)2D3, 5
lg/ml cerulenin or the combination of two for 24 h. After the treat-
ments, RNA was isolated and the expression of FACL3 mRNA was
measured using real-time quantitative PCR. The results represent three
independent experiments and normalized to housekeeping gene
GAPDH. Cerulenin showed no signiﬁcant eﬀect on vitamin D3 up-
regulation of FACL3 expression.
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acid-induced repression of FAS expression in the presence
of vitamin D3
There are several substrates preferential for FACL3 in the
synthesis of long chain fatty acyl-CoAs [16]. In our previous
study, myristic acid, one of the preferential substrates for
FACL3, was applied to measure the enzyme activity and in-
dicated that the formation of myristoyl-CoA was signiﬁcantly
increased at indicated time points (48, 96, and 144 h) in the
presence of vitamin D3 in human prostate cancer LNCaP cells
[14]. To investigate the eﬀect of long chain fatty acyl-CoAs
formed by FACL3 on vitamin D3 inhibition of FAS mRNA
expression, myristic acid and triacsin C were used to treat
LNCaP cells in the presence or absence of vitamin D3. Myristic
acid showed no signiﬁcant eﬀect on vitamin D3 repression of
FAS mRNA expression at 24 h, but enhanced the decrease in
FAS mRNA by vitamin D3 at 48 h (Fig. 3). Triacsin C, anFig. 3. Enhancement in vitamin D3 inhibition of FAS expression by
myristic acid is attributable to the formation of myristoyl-CoA in
prostate cancer LNCaP cells. LNCaP cells were grown in RPMI-1640
medium supplemented with 10% FBS and treated with 10 nM
1a,25(OH)2D3, 10 lM myristic acid, 1 lM triacsin C or the combi-
nations as indicated. FAS mRNA expression was measured using real-
time quantitative PCR. The results represent three independent
experiments and normalized to housekeeping gene GAPDH. At 24 h,
myristic acid showed to attenuate slightly but not signiﬁcantly the vi-
tamin D3-repression of FAS expression. The downregulation of FAS
expression by vitamin D3 was signiﬁcantly enhanced by myristic acid
at 48 h and this enhancement was abrogated by triacsin C. Myristic
acid alone showed no signiﬁcant eﬀect on FAS expression.inhibitor of FACL3 activity, abrogated the eﬀect of myristic
acid on vitamin D3 inhibition of FAS expression (Fig. 3).
Neither myristic acid nor triacsin C alone had signiﬁcant eﬀect
on the expression of FAS mRNA. The data suggest that
myristoyl-CoA, but not myristic acid, possesses an ability to
inhibit FAS expression and the formation of myristoyl-CoA
by FACL3 contributes to the downregulation of FAS ex-
pression by vitamin D3 in LNCaP cells. Myristic acid had no
considerable eﬀect on vitamin D3 upregulation of FACL3
expression in LNCaP cells (data not shown).4. Discussion
Vitamin D3 is a potential anti-cancer compound due to its
antiproliferative function. In our previous studies, we investi-
gated the genes regulated by 1a,25(OH)2D3 in prostate cancer
LNCaP cells using cDNA microarray and found that two fatty
acid metabolic enzymes, FAS and FACL3, were regulated by
vitamin D3. The further studies suggested that FAS and
FACL3 were involved in vitamin D3 inhibition of LNCaP cells
growth [14,15]. FAS catalytically synthesizes fatty acid and
FACL3, a downstream enzyme of FAS, converts long chain
fatty acid to the corresponding acyl-CoA. A number of studies
indicated that fatty acid synthesis was inhibited by long chain
fatty acyl-CoAs [5]. This led us to further investigate whether
there is a relationship between the regulation of FAS and
FACL3 expressions by vitamin D3.
Inhibition of FACL3 activity by triacsin C resulted in a
complete abolishment of the repression of FAS mRNA ex-
pression by vitamin D3. Cerulenin, an inhibitor of FAS ac-
tivity, had no signiﬁcant eﬀect on vitamin D3 upregulation of
FACL3 mRNA expression. Neither the eﬀect of triacsin C on
vitamin D3 increase of FACL3 mRNA nor the eﬀect of ceru-
lenin on the vitamin D3 decrease of FAS mRNA was seen.
These suggest that the downregulation of FAS expression by
vitamin D3 is mediated by FACL3 in LNCaP cells. This is
consistent with our previous ﬁndings that the action of vitamin
D3 on FAS expression is not direct [15]. In vitamin D3-re-
sponsive human prostate cancer PC3 cells, which are androgen
receptor-negative in contrast to LNCaP cells, no regulation of
FAS expression by vitamin D3 was found, consistent with no
vitamin D3 regulation of FACL3 expression in PC3 cells. Vi-
tamin D3 increases both mRNA expression and the activity of
FACL3 [14]. The increase in the FACL3 activity by vitamin
D3 results in an increase in the formation of long chain fatty
acyl-CoAs, which may inhibit FAS mRNA expression. My-
ristic acid, one of the substrates preferential for FACL3, had
no signiﬁcant eﬀect on the decrease of FAS mRNA by vitamin
D3 at 24 h, but enhanced the decrease in FAS mRNA by vi-
tamin D3 at 48 h. This is consistent with our previous study
that the formation of myristoyl-CoA is not signiﬁcantly ele-
vated at 24 h and signiﬁcantly elevated at 48 h in the presence
of vitamin D3 [14]. Myristic acid-induced enhancement in the
vitamin D3-repression of FAS mRNA expression was com-
pletely abolished by triacsin C, indicating that the formation of
myristoyl-CoA contributes to vitamin D3 downregulation of
FAS expression. The data suggest that the downregulation of
FAS mRNA by vitamin D3 is the result of feedback inhibition
of FAS expression by long chain fatty acyl-CoAs formed
during vitamin D3-upregulation of FACL3 in LNCaP cells.
Fig. 4. Schematic illustration of the proposed mechanism of vitamin
D3 inhibition of FAS expression in human prostate cancer LNCaP
cells. FACL3 expression is upregulated by vitamin D3, increased
FACL3 expression enhances the formation of long chain fatty acyl-
CoAs, which regulate FAS expression by means of feedback inhibition,
resulting in the decrease in FAS expression which regulates cell growth
and apoptosis.
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CoAs is evident. Some studies [5,11,17] suggest that long chain
fatty acyl-CoAs inhibit fatty acid synthesis in terms of feed-
back inhibition of ACC, the ﬁrst enzyme in fatty acid synthesis
pathway. Based on this study, we suggest that long chain fatty
acyl-CoAs formed by FACL3 during its upregulation by vi-
tamin D3 repress mRNA expression of FAS, the second en-
zyme in fatty acid synthesis pathway. Inhibition of FAS
expression by long chain fatty acyl-CoAs may represent one
mechanism of inhibition of fatty acid synthesis. Some results
suggest that inhibition of ACC by long chain fatty acyl-CoA is
due to the decrease in amounts of enzyme, the amounts of
changes in ACC caused by the alteration in dietary fat are
accompanied with similar amounts of changes in FAS [3].
These imply that inhibition of ACC by long chain fatty acyl-
CoAs might be due to a repression of ACC mRNA expression
and a link between inhibitions of FAS and ACC by long chain
fatty acyl-CoAs. The direct inhibition of ACC by long chain
fatty acyl-CoA has been reported [18]. It might be possible that
the inhibition of ACC by long chain fatty acyl-CoAs could
aﬀect FAS expression and result in the decrease in FAS
mRNA. The relationship between inhibitions of ACC and
FAS by long chain fatty acyl-CoAs remains to be investigated.
FAS is overexpressed in prostate cancer and associated with
prostate cancer development [19–22]. Inhibition of FAS ac-
tivity or knockdown of FAS mRNA results in human prostate
cancer LNCaP cell growth inhibition/apoptosis [15,23]. We
found previously that the expression of FACL3 was upregu-
lated by vitamin D3 and contributed to the inhibitory eﬀect of
vitamin D3 in LNCaP cells [14]. In this study, we unravell that
long chain fatty acyl-CoAs which are formed due to the in-
crease in FACL3 expression by vitamin D3 decrease FAS
mRNA. This suggests that the contribution of FACL3 to vi-
tamin D3 inhibition of LNCaP cells growth, at least in part, isdue to long chain fatty acyl-CoA-mediated decrease in FAS
expression, and could be one mechanism of FACL3 in vitamin
D3 antiproliferative eﬀect. Taken together, we conclude that
the upregulation of FACL3 by vitamin D3 results in the in-
crease in long chain fatty acyl-CoAs, which repress FAS
mRNA expression by means of feedback inhibition. The de-
crease in FAS expression might contribute to the inhibition of
human prostate cancer LNCaP cell growth by vitamin D3
(Fig. 4).Acknowledgements: We express our appreciation for the technical as-
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